Abstract
Pulmonary hypertension (PH) is an often devastating comorbidity in patients with interstitial lung disease (ILD). The prevalence of PH varies widely across the spectrum of ILDs, and it is thought that there are common pathobiological processes, which contribute to both progressive interstitial fibro
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
